Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunization against oxidized LDL in lysosomal lipid diseases and metabolic disorders
2015-004846-25Phase 4Completed
- Sponsor
- Maastricht University
- Start
- Mar 2016
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, single-arm trial of pneumococcal 13-valent conjugate vaccine in familial hypercholesterolemia (FH) and lysosomal storage disease (LSD), sponsored by Maastricht University. Primary endpoint: Effect of reduced plasma oxidized LDL on inflammation and cholesterol metabolism. Started Mar 2016; status: completed.
02
Drugs
pneumococcal 13-valent conjugate vaccine
03
Conditions
familial hypercholesterolemia (FH)lysosomal storage disease (LSD)
Beyond the preview
Go deeper on 2015-004846-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004846-25.